

Speculative

Refer to key risks on page 4 and general bio technology warning on page 6. Speculative securities may not be suitable for retail clients

Analyst

John Hester 612 8224 2871

Viralytics (VLA)

Merck Collaboration Validates Strategy

Authorisation

TS Lim 612 8224 2810

Recommendation

Buy (unchanged)

Price

\$0.68

Valuation

\$0.96 (unchanged)

Risk

Speculative

GICS Sector

Pharmaceuticals & Biotechnology

Expected Return

| | |
|-----------------------|-------------|
| Capital growth | 41% |
| Dividend yield | 0.0% |
| Total expected return | 41% |


Company Data & Ratios

| | |
|------------------------|------------------------|
| Enterprise value | \$101m |
| Market cap | \$125m |
| Issued capital | 184.4m |
| Free float | 100% |
| Avg. daily val. (52wk) | \$154,000 |
| 12 month price range | \$0.28 - \$0.93 |

Price Performance

| | (1m) | (3m) | (12m) |
|----------------|------|-------|--------|
| Price (A\$) | 0.63 | 0.71 | 0.30 |
| Absolute (%) | 7.94 | -4.23 | 130.51 |
| Rel market (%) | 6.89 | 3.99 | 135.76 |

Absolute Price



SOURCE: IRESS

Merck and VLA to contribute drug in STORM

The treatment landscape for many of the more common cancers continues to expand thanks to the success of the combination of checkpoint inhibitors drugs such as Merck's anti – PD1 therapy Keytruda with new drugs such as CAVATAK. Friday's announcement that Merck and Viralytics are to collaborate in a combination study of CAVATAK and Keytruda while not surprising, is a significant validation of Viralytics' clinical trial program and its strategy to initiate the STORM study.

In addition to the obvious efficacy CAVATAK has now displayed in clinical trials, the one property CAVATAK possess which makes it highly suitable for combination with Keytruda is its suitability for intravenous administration. The STORM study was designed to evaluate the efficacy of CAVATAK under this mode of administration – initially as a monotherapy where investigators were looking for signals of efficacy, then in the second stage, possibly in combination with either a chemotherapy or a checkpoint inhibitor therapy.

At this time Viralytics has disclosed only very limited data from the early patients in the STORM study. As Merck has now decided to contribute its drug pembrolizumab (Keytruda) to the second stage of the study, it is not unreasonable to conclude that subsequent results from STORM have continued to provide encouraging results. The theory is that CAVATAK up regulates immune system activity in patients that have been heavily pre-treated with surgery and various regimes of chemotherapy. Upregulation of the immune system prior to the administration of Keytruda may result in improved efficacy of the combination relative to either drug as a monotherapy.

The initiation of this clinical trial collaboration is not expected to effect the progress of the CAPRA study – also involving a combination of CAVATAK and Keytruda in late stage Melanoma.

Maintain Buy rating and Price Target – No changes to earnings or price target following this announcement. We continue to believe VLA is significantly undervalued.

Earnings Forecast

| June Year End | FY15 | FY16e | FY17e | FY18e |
|-----------------------|--------|--------|-------|-------|
| Revenues | 2.5 | 3.0 | 50.0 | 60.0 |
| EBITDA \$m | -4.4 | -5.5 | 41.5 | 50.5 |
| NPAT (underlying) \$m | -4.3 | -5.4 | 41.1 | 50.1 |
| NPAT (reported) \$m | -4.3 | -5.4 | 41.1 | 50.1 |
| EPS underlying (cps) | -2.3 | -2.9 | 22.3 | 27.2 |
| EPS growth % | -50% | 26% | -861% | 22% |
| PER (x) | -29.2 | -23.2 | 3.0 | 2.5 |
| FCF yield (%) | -4% | -4% | 33% | 42% |
| EV/EBITDA (x) | -23.0 | -18.4 | 2.4 | 2.0 |
| Dividend (cps) | - | - | - | - |
| Franking | 0% | 0% | 0% | 0% |
| Yield % | 0.0% | 0.0% | 0.0% | 0.0% |
| ROE % | -17.2% | -27.8% | 67.9% | 45.3% |

SOURCE: BELL POTTER SECURITIES ESTIMATES

Background to STORM

STORM Phase I/II Trial (Systemic Treatment of Resistant Malignancies)

The following is an extract from our initiation report on VLA from March 2014.

This trial is investigating the efficacy of CAVATAK either with or without a chemotherapy agent across a variety of solid tumours including non small cell lung, colorectal, breast and prostate. The trial is being run in the UK and commenced in early 2014.

The study is being conducted at three leading cancer centres in the UK. The lead study investigators are prominent oncologists Professor Hardev Pandha (The University of Surrey), Professor Kevin Harrington (The Institute of Cancer Research and The Royal Marsden, London) and Professor Alan Melcher (St James's University Hospital, Leeds).

Earlier Phase I trials using single intravenous escalating doses in just 10 patients showed good tolerability and some encouraging preliminary data on tumour targeting, particularly in melanoma patients. Patients in this suffered from late stage melanoma, colorectal, breast or prostate cancers.

Viralytics researchers have previously shown successful tumour targeting and cancer cell destruction following intravenous delivery of CAVATAK to mice bearing human melanoma and breast cancer tumours.

CAVATAK has a defined extracellular targeting mechanism in binding to cancer cell surface ICAM-1. In contrast, other oncolytic viruses such as T-Vec and Reolysin rely on intracellular mechanisms for selective tumour cell targeting, which may result in lower efficacy in tumour cell targeting. Furthermore, a majority of cancer patients have pre-existing antibodies to both T-Vec and Reolysin questioning successful intravenous virus delivery. Pre-existing antibody levels to CAVATAK are much lower, in the order of about 15-20% of the patient populations, offering this as a potential advantage to systemic viral delivery.

Figure 1 - Summary of Phase clinical trials

| | Type | Disease stage | Indication | Patients |
|--------|---------------------------------------|---------------|--|----------|
| VLA-01 | Single dose intratumoural | Stage IV | Melanoma | 2 |
| VLA-02 | Single dose intratumoural | Stage IV | Melanoma | 3 |
| VLA-03 | Multi dose escalational intratumoural | Stage IV | Melanoma | 9 |
| VLA-04 | Single dose intravenous | Stage IV | Melanoma, Colorectal, Breast, Prostate | 10 |
| VLA-05 | Multidose intratumoural | Stage IV | Head and Neck | 4 |

SOURCE: COMPANY DATA

The trial will consist of 2 sequential parts: the first part (VLA009A) is a study of intravenous CVA21 as a single agent for the treatment of 4 different advanced solid tumours; the second part (VLA009B) is a study of intravenous CVA21 in combination with cytotoxic therapy appropriate for the solid tumour selected in the first part.

Both parts will be open-label, multi-centre, ascending dose escalation (3+3 design) dose-finding and signal-seeking studies. In the final cohort for VLA009A, there must be a minimum of three subjects in each of the four solid tumours (NSCLC, prostate, bladder and melanoma) who have biopsy of an accessible lesion and complete one cycle of treatment before enrolment is completed.

VLA-009A: This part is expected to enrol from 18 to 27 subjects.

VLA009B: This part is expected to enrol from 9 to 18 subjects.

Merck Collaboration

The FDA approved Keytruda for the treatment of non small cell lung carcinoma (NSCLC) in October 2015. Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. NSCLC is the most common type of lung cancer. Keytruda is also approved for late stage melanoma.

The second part of the STORM study has now been redesigned to assess the intravenous delivery of CAVATAK in combination with Keytruda in advanced non small cell lung cancer or Metastatic Bladder cancer. The final expansion cohort of 80 patients across both indications is new. The aim of the study is to establish a recommended dose regime for the combination and to evaluate efficacy. Patient biopsies will be assessed for change in tumour microenvironment.

Pending results from the STORM study, the parties may extend the collaboration to include a potential phase III clinical trial for one or more indications.

In our view the most significant risk in the STORM trial was whether sufficient quantity of the drug (i.e. therapeutic dose) would reach the tumour. We await further data in this regard and this should be available within weeks. Viralytics will be presenting a poster at an upcoming immunotherapy conference.

COMMERCIAL TERMS NOT DISCLOSED

The key for investors is to understand what rights and obligations VLA has negotiated as part of the collaboration. VLA has in excess of \$20m in cash and a well established trial program underway with support from a high quality shareholder register. CEO Malcolm McColl has therefore completed this agreement from a position of strength.

Also interesting that rather than initiate a whole new study, Merck agreed to collaborate on an existing study – which it does not control. Rather, Viralytics remains the sponsor of the STORM study.

If the clinical trial in the two indications is successful it is likely the two drugs would be approved as a combination with either party benefiting from additional drug sales. i.e. The absence of any cash up front or discussion of a license agreement in this announcement leads us to believe that VLA intends to build out the data dossier before partnering. As the data dossier builds and continues to show promising results, a partnering deal at this point may well undervalue the asset.

It remains to be seen how this collaboration develops in relation to the funding of an approval study. Nevertheless should the collaboration study prove successful we expect that Viralytics will have an abundance of options for further development of CAVATAK, all of which should result in further value creation for shareholders.

Viralytics Limited

The company has one candidate in the clinic being CAVATAK (CVA21).

CAVATAK is an oncolytic (cancer cell destroying) virus with a dual mode of action. The virus replicates inside the cancer cell eventually causing the cell to lyse (or rupture). The lytic process releases tumour cell debris that may illicit a response by the patient's immune system against the tumour, providing a secondary but important immunotherapeutic effect. Such an immune response may be enhanced by the systemic circulation of tumour cell components complexed with foreign CAVATAK proteins or simply the presence of actively replicating virus within the tumour cell.

The preclinical studies show that CVA21 binds to the intracellular adhesion molecule (ICAM-1) receptor which is over expressed in many human cancer cells. Normal viral defences limit the spread of the virus in non-cancerous cells, hence CAVATAK is highly targeted towards any cancer cell which expresses the ICAM-1 receptor. CAVATAK does not have a material effect on normal cell activity as evidenced by its relatively benign side effect profile observed in current clinical program.

By virtue of its size and non-enveloped viral shell, CAVATAK is suitable for administration via direct injection into the tumour (intratumoural injection) or by intravenous (IV) administration. In particular suitability for IV administration differentiates CAVATAK from Amgen's T-Vec, making CAVATAK also suitable for treatment of other solid cancers types that are not accessible to treatment via direct injection. This topic is the subject of the STORM study.

CAVATAK is a proprietary formulation of the genetically unmodified human Coxsackievirus A21 (CVA21). CVA21 is a naturally occurring virus that is associated with common head cold. Its oncolytic properties were discovered by the scientific team led by Chief Science Officer – Professor Darren Shafren at the company's research facilities in Newcastle, Australia. The initial preclinical studies were conducted on *in vitro* cultures of human cancer cells and then later in *in vivo* testing on grafted human cancers in mice.

Valuation is determined using a discounted cash flow model.

RISK AREAS

New technology may emerge. There are many clinical trials underway around the globe in the treatment of melanoma. There is the potential that one or more of these trials may yield outcomes that render CAVATAK and other drugs for the treatment of metastatic melanoma obsolete.

CAVATAK is untested in a large randomised trial. The interim results from CAVATAK are encouraging and supportive of further testing. It is not uncommon for cancer drugs to fail in large, randomised Phase III trials. Successful results in small Phase II trials are not a precursor to success in larger Phase III trials.

The long term side effect profile of CAVATAK is unknown. There is no long term data on the side effect profile of CAVATAK, hence we do not know if it will have any long term side effects that are yet to emerge.

Viralytics has one drug in the clinic. If CAVATAK does not show efficacy in future clinical trials or fails to come to market, it is likely the company would be of less value.

Table 1 - Financial summary

| Profit & Loss (A\$m) | | | | | | Last sale 08/11/2015 | |
|-------------------------------|-------------|--------------|--------------|-------------|--------------|--------------------------------|--|
| Year Ending June | FY14 | FY15 | FY16e | FY17e | FY18e | Recommendation | Buy (Spec) |
| Transaction income | - | - | - | 50.0 | 60.0 | Issued Capital | 184.5 |
| R&D Incentive payments | 2.5 | 2.5 | 3.0 | - | - | Market Cap | 125.4 |
| Total revenues | 2.5 | 2.5 | 3.0 | 50.0 | 60.0 | Profitability Ratios | |
| Total revenues | 2.5 | 2.5 | 3.0 | 50.0 | 60.0 | Year Ending June | FY14 FY15 FY16e FY17e FY18e |
| Clinical trials | 2.7 | 3.4 | 5.0 | 5.0 | 6.0 | EBITDA margin | 0.0% 0.0% 0.0% 0.0% 0.0% |
| Other expenses | 5.3 | 3.5 | 3.5 | 3.5 | 3.5 | EBIT margin | 0.0% 0.0% 0.0% 0.0% 0.0% |
| EBITDA | -5.5 | -4.4 | -5.5 | 41.5 | 50.5 | EBIT growth | 0.0% 0.0% 0.0% 0.0% 0.0% |
| Depreciation | - | 0.0 | 0.0 | 0.0 | 0.0 | Valuation Ratios (A\$m) | |
| Amortisation | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | Reported EPS (cps) | -4.7 -2.3 -2.9 22.3 27.2 |
| EBIT | -5.9 | -4.8 | -5.9 | 41.1 | 50.1 | Normalised EPS (cps) | -4.7 -2.3 -2.9 22.3 27.2 |
| Net interest | 0.3 | 0.5 | 0.5 | - | - | EPS growth (%) | -7% -50% 26% -861% 22% |
| Pre tax profit | -5.6 | -4.3 | -5.4 | 41.1 | 50.1 | PE(x) | -14.5 -29.2 -23.2 3.0 2.5 |
| Tax expense | - | - | - | - | - | EV/EBITDA (x) | -18.5 -23.0 -18.4 2.4 2.0 |
| NPAT-normalised | -5.6 | -4.3 | -5.4 | 41.1 | 50.1 | EV/EBIT (x) | -17.2 -21.1 -17.2 2.5 2.0 |
| Net abnormal items | - | - | - | - | - | NTA (cps) | 14.4 12.4 9.7 32.2 59.7 |
| Reported NPAT | -5.6 | -4.3 | -5.4 | 41.1 | 50.1 | P/NTA (x) | 4.7 5.5 7.0 2.1 1.1 |
| Cashflow (A\$m) | | | | | | Book Value (cps) | 15.7 13.5 10.6 32.9 60.1 |
| Gross cashflow | -5.7 | -5.0 | -5.5 | 41.5 | 52.2 | Price/Book (x) | 4.3 5.0 6.4 2.1 1.1 |
| Net interest | 0.3 | 0.5 | 0.5 | 0.0 | 0.0 | DPS (cps) | - - - - - |
| Tax paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | Payout ratio % | 0% 0% 0% 0% 0% |
| Operating cash flow | -5.4 | -4.5 | -5.0 | 41.5 | 52.2 | Dividend Yield % | 0.0% 0.0% 0.0% 0.0% 0.0% |
| Maintenance capex | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | Franking % | 0% 0% 0% 0% 0% |
| Free cash flow | -5.4 | -4.6 | -5.0 | 41.5 | 52.2 | FCF yield % | -4% -4% -4% 33% 42% |
| Business acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | Performance Ratios | |
| Proceeds from issuance | 25.1 | 0.0 | 0.0 | 0.0 | 0.0 | ROA | -18.8% -16.1% -25.5% 66.0% 44.8% |
| Movement in borrowings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ROE | -19.4% -17.2% -27.8% 67.9% 45.3% |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ROIC | -20.4% -19.3% -30.3% 67.9% 45.3% |
| Issuance cost | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | Net debt/Equity | 0% 0% 0% 0% 0% |
| Change in cash held | 19.7 | (4.5) | (5.0) | 41.5 | 52.2 | Net debt/Assets | 0% 0% 0% 0% 0% |
| Cash at beginning of period | 5.1 | 24.4 | 21.6 | 16.6 | 58.1 | Gearing | net cash net cash net cash net cash net cash |
| Cash at year end | 24.4 | 21.6 | 16.6 | 58.1 | 110.3 | Net debt/EBITDA (x) | n/a n/a n/a n/a n/a |
| Balance Sheet (A\$m) | | | | | | Interest cover (x) | n/a n/a n/a n/a n/a |
| Cash | 24.3 | 21.6 | 16.6 | 58.1 | 110.3 | | |
| Receivables | 2.8 | 2.9 | 2.9 | 2.9 | 0.5 | | |
| Inventory | - | - | - | - | - | | |
| Property, Plant and Equipment | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | | |
| Intangible assets | 2.4 | 2.0 | 1.6 | 1.2 | 0.8 | | |
| Other | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | | |
| Total assets | 29.7 | 26.6 | 21.2 | 62.3 | 111.7 | | |
| Trade payables | 0.8 | 1.7 | 1.7 | 1.7 | 1.0 | | |
| Provision for income tax | - | - | - | - | - | | |
| Debt - interest bearing debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Total Liabilities | 0.8 | 1.7 | 1.7 | 1.7 | 1.0 | | |
| Net Assets | 28.9 | 24.9 | 19.5 | 60.6 | 110.7 | | |
| Share capital | 87.0 | 87.6 | 87.6 | 87.6 | 87.6 | | |
| Convertible notes | 0.6 | - | - | - | - | | |
| Retained earnings | (61.9) | (66.2) | (71.6) | (30.5) | 19.6 | | |
| Reserves | 3.1 | 3.5 | 3.5 | 3.5 | 3.5 | | |
| Shareholders Equity | 28.8 | 24.9 | 19.5 | 60.6 | 110.7 | | |

SOURCE: BELL POTTER SECURITIES ESTIMATES

Recommendation structure

Buy: Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

Hold: Expect total return between -5% and 15% on a 12 month view

Sell: Expect <-5% total return on a 12 month view

Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.

Such investments may carry an exceptionally high level of capital risk and volatility of returns.

Research Team

| Staff Member | Title/Sector | Phone | @bellpotter.com.au |
|--------------------|-----------------------|----------------|--------------------|
| TS Lim | Head of Research | 612 8224 2810 | tslim |
| Industrials | | | |
| Sam Haddad | Industrials | 612 8224 2819 | shaddad |
| John O'Shea | Industrials | 613 9235 1633 | joshea |
| Chris Savage | Industrials | 612 8224 2835 | csavage |
| Jonathan Snape | Industrials | 613 9235 1601 | jsnape |
| Sam Byrnes | Industrials | 612 8224 2886 | sbyrnes |
| Bryson Calwell | Industrials Associate | 613 9235 1853 | bcalwell |
| John Hester | Healthcare | 612 8224 2871 | jhester |
| Tanushree Jain | Healthcare/Biotech | 612 8224 2849 | tnjain |
| Financials | | | |
| TS Lim | Banks/Regionals | 612 8224 2810 | tslim |
| Lafitani Sotiriou | Diversified | 613 9235 1668 | Isotiriou |
| Resources | | | |
| David Coates | Resources | 613 9235 1833 | showe |
| Peter Arden | Resources | 613 9235 1731 | parden |
| Associates | | | |
| Tim Piper | Associate Analyst | 612 8224 2825 | tpiper |
| Hamish Murray | Associate Analyst | 61 3 9256 8761 | hmurray |

Bell Potter Securities Limited

ACN 25 006 390 7721

Level 38, Aurora Place
88 Phillip Street, Sydney 2000

Telephone +61 2 9255 7200

www.bellpotter.com.au

The following may affect your legal rights. Important Disclaimer:

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. In Hong Kong this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

Disclosure of interest:

Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

Disclosure: Bell Potter Securities acted as Lead manager of the 2014 Capital Raising and received fees for that service.

Biotechnology Risk Warning:

The stocks of biotechnology companies without revenue streams from product sales or ongoing service revenue should always be regarded as speculative in character. Since most biotechnology companies fit this description, the speculative designation also applies to the entire sector. The fact that the intellectual property base of a typical biotechnology company lies in science and not generally regarded as accessible to the layman adds further to the riskiness with which biotechnology investments ought to be regarded. Stocks with 'Speculative' designation are prone to high volatility in share price movements. Clinical and regulatory risks are inherent in biotechnology stocks. Biotechnology developers usually seek US FDA approval for their technology which is a long and arduous three phase process to prove the safety, effectiveness and appropriate application or use of the developed drug, and even after approval a drug can be the subject of an FDA investigation of subsequently discovered possible links between the drug and other un-previously diagnosed diseases. Investors are advised to be cognisant of these risks before buying such a stock including **Viralytics** (of which a list of specific risks is highlighted within).

ANALYST CERTIFICATION:

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.